<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46916">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495454</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_GAEL</org_study_id>
    <secondary_id>2014-005697-10</secondary_id>
    <nct_id>NCT02495454</nct_id>
  </id_info>
  <brief_title>GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma</brief_title>
  <acronym>FIL_GAEL</acronym>
  <official_title>GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma A Phase II Study of the Fondazione Italiana Linfomi (FIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GA101-miniCHOP regimen for the treatment of elderly unfit patients with diffuse large B-cell
      non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Complete Response Rate after 10 infusions of GA101 and 6 cycles of miniCHOP. The response rate to therapy will be based a central Independent Review Committee of response that will not consider the results of FDG-PET but will only use the conventional CT scan images (International Criteria, B. Cheson, JCO 1999)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Rate of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial (PRR) and Overall Response Rate (ORR)</measure>
    <time_frame>36 months from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from 60 months from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>from 60 months from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living (ADL)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Change in ADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental Activities of Daily Living (IADL)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Change in IADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Illness Rating Scale (CIRS)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Change in CIRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire for quality of life (EORTC QLQ C30)</measure>
    <time_frame>36 months from first patient in</time_frame>
    <description>Change in quality of life (QoL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>CD20 Positive Diffuse Large B-cell Lymphoma</condition>
  <condition>Elderly Unfit Patients</condition>
  <arm_group>
    <arm_group_label>Ga101-miniCHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).
GA101-miniCHOP regimen:
Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os
Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os
Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga101</intervention_name>
    <arm_group_label>Ga101-miniCHOP</arm_group_label>
    <other_name>Obinutuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven CD20 positive Diffuse Large B-cell Lymphoma and Follicular
             grade IIIB lymphoma, according to WHO classification (local pathologist)

          2. Age ≥ 65 years

          3. No previous treatment

          4. CGA assessment performed before starting treatment

          5. UNFIT patients defined as follows:

             Age &gt; 80 years with FIT profile, i.e. ADL =6 residual functions IADL=8 residual
             functions CIRS: no comorbidity of grade 3-4 and &lt;5 of grade 2 or Age &lt; 80 with UNFIT
             profile, i.e ADL &gt; 5 residual functions IADL &gt; 6 residual functions CIRS: no
             comorbidity of grade 3-4 and 5-8 co-morbidities of grade 2

          6. Ann Arbor Stage I with bulky, II-IV

          7. At least one bi-dimensionally measurable lesion defined as &gt; 1.5 cm in its largest
             dimension on CT scan

          8. ECOG performance status of 0, 1, or 2

          9. Adequate hematologic function (unless caused by bone marrow infiltrate), defined as
             follows:

             Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x
             109/L

         10. LVEF &gt;50%

         11. Ability and willingness to comply with the study protocol procedure

         12. Life expectancy &gt; 6 months

         13. Accessibility of patient for treatment and follow up

         14. Written informed consent

        Exclusion Criteria:

          1. History of severe allergic or anaphylactic reactions to humanized or murine
             monoclonal antibodies or known sensitivity or allergy to murine products

          2. Contraindication to any of the individual components of CHOP, including prior receipt
             of anthracyclines

          3. History of other malignancies within 5 years prior to study entry except for
             adequately treated carcinoma in situ of the cervix or basal or squamous cell skin
             cancer

          4. Stage I without bulky

          5. Patients with transformed lymphoma

          6. Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation

          7. Previous exposure to cytotoxic agents

          8. Suspect or clinical evidence of CNS involvement by lymphoma

          9. HBsAg, HCV or HIV positivity; isolated HBcAb positivity is accepted only with
             concomitant treatment with Lamivudine

         10. AST /ALT &gt; twice upper the normal range; bilirubin &gt; twice upper the normal range;
             serum creatinine &gt; 2.5 mg /dl (unless these abnormalities were related to the
             lymphoma)

         11. Evidence of any severe active acute or chronic infection

         12. Concurrent co-morbid medical condition which might exclude administration of full
             dose chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Merli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ematologia - IRCCS Arcispedale Santa Maria Nuova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caterina Mammi, PHD</last_name>
    <email>Caterina.Mammi@asmn.re.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Uffici Studi FIL</last_name>
    <email>segreteria@filinf.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. Policlinico Consorziale</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgina Specchia, MD</last_name>
      <phone>+39 080-5593471</phone>
      <email>giorgina.specchia@uniba.it</email>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Rosti, MD</last_name>
      <phone>0363-424351</phone>
      <email>jacopo_mariotti@ospedale.treviglio.bg.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Rosti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Perrino</name>
      <address>
        <city>Brindisi</city>
        <state>BR</state>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Melpignano, MD</last_name>
      <phone>0831-537507</phone>
      <email>angelamelpignano@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Angela Melpignano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tucci, MD</last_name>
      <phone>+39 0303996269</phone>
      <email>alessandra.tucci@spedalicivili.brescia.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Tucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncoematologia - Fondazione di Ricerca e Cura &quot;Giovanni Paolo II&quot;</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Storti, MD</last_name>
      <email>sstorti@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Storti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Di Raimondo, Prof</last_name>
      <email>diraimon@unict.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica ed Ematologia Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vittorio Zilioli, MD</last_name>
      <phone>+39 02 - 64442668</phone>
      <email>vittorioruggero.zilioli@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Zilioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesca Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Cellini, MD</last_name>
      <phone>0544285330</phone>
      <email>c.cellini@ausl.ra.it</email>
    </contact>
    <investigator>
      <last_name>Claudia Cellini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asmn-Irccs</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>43123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Merli, MD</last_name>
      <phone>0522-296618</phone>
      <email>merli.francesco@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia 1U - AO Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Cavallo, MD</last_name>
      <email>f.cavallo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Ematologia - AO Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Umberto Vitolo, MD</last_name>
      <email>uvitolo@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Umberto Vitolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati, MD</last_name>
      <phone>+39 0744-205971</phone>
      <email>marinal@unipg.it</email>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ente ecclesiastico Ospedale generale regionale Miulli</name>
      <address>
        <city>Acquaviva delle fonti (BA)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giuseppe Polimeno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Salvi, MD</last_name>
      <phone>+39 0131206294</phone>
      <email>segreteria@filinf.it</email>
    </contact>
    <investigator>
      <last_name>Flavia Salvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>g.gini@ospedaliriuniti.marche.it</email>
    </contact>
    <investigator>
      <last_name>Guido Gini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di riferimento Oncologico - Oncologia Medica A</name>
      <address>
        <city>Aviano (PN)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCC Istituto tumori Ematologia</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Attilio Guarini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Barletta</name>
      <address>
        <city>Barletta</city>
        <zip>76121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <phone>3464142695</phone>
      <email>giuseppetarantini@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Degli Infermi</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annarita Conconi</last_name>
      <email>annarita.conconi@aslbi.piemonte.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Osp. Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giuseppina Cabras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Quintavalle</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USL 6 Livorno Centro Aziendale Ematologia</name>
      <address>
        <city>Livorno</city>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Capochiani, MD</last_name>
      <phone>0586-223416</phone>
      <email>e.capochiani@usl6.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Capochiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Area Vasta Romagna e IRST</name>
      <address>
        <city>Meldola (FC)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerardo Musuraca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Matteucci, MD</last_name>
      <phone>0223902660-3356</phone>
      <email>paola.matteucci@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Paola Matteucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Luminari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia - Università del Piemonte Orientale</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano, Prof</last_name>
      <email>gaidano@med.unipmn.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Oncologico Veneto (Iov)</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dario Marino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncoematologia e TMO Dopartimento Oncologia La Maddalena</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Musso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maurizio Musso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO di Perugia S. Maria della misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonardo Flenghi, MD</last_name>
      <phone>075-5784110</phone>
      <email>flenghi@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Leonardo Flenghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Spirito Santo</name>
      <address>
        <city>Pescara</city>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Angrilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ausl Di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Annalisa Arcari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ausl Di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47924</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>annalia.molinari@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Molinari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia - A.O. Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agostino Tafuri, Prof.</last_name>
      <phone>0633775113</phone>
      <email>agostino.tafuri@ospedalesantandrea.it</email>
    </contact>
    <investigator>
      <last_name>Agostino Tafuri, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alberto Fabbri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.Cardinale Panico Ematologia e centro trapianti</name>
      <address>
        <city>Tricase (LE)</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Maria Della Misericordia Di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Zaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Merli, MD</last_name>
      <email>michele.merli@ospedale.varese.it</email>
    </contact>
    <investigator>
      <last_name>Michele Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 24, 2016</lastchanged_date>
  <firstreceived_date>June 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
